SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 7196
  • 2
    Albertsen P. Androgen deprivation in prostate cancer – step by step. N Engl J Med 2009; 360: 25724
  • 3
    Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005; 23: 814651
  • 4
    Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212
  • 5
    Stephenson AJ, Kattan MW, Eastham JA et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 43005
  • 6
    Lucas A, Petrylak DP. The case for early chemotherapy for the treatment of metastatic disease. J Urol 2006; 176: S725
  • 7
    Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 250613
  • 8
    Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 175664
  • 9
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 151320
  • 10
    Armstrong AJ, Garrett-Mayer ES, Yang YC, De Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396403
  • 11
    Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 76671
  • 12
    Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009; 9: 23749
  • 13
    Manin M, Baron S, Goossens K et al. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 2002; 366: 72936
  • 14
    Wen Y, Hu MC, Makino K et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 68415
  • 15
    Yang L, Xie S, Jamaluddin MS et al. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 2005; 280: 3355865
  • 16
    Xu Y, Chen SY, Ross KN, Balk SP. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res 2006; 66: 778392
  • 17
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 101127
  • 18
    Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 203949
  • 19
    Burton JB, Priceman SJ, Sung JL et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008; 68: 782837
  • 20
    Di JM, Zhou J, Zhou XL et al. Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer. Arch Med Res 2009; 40: 26875
  • 21
    Muders MH, Zhang H, Wang E, Tindall DJ, Datta K. Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res 2009; 69: 60428
  • 22
    Jerome L, Shiry L, Leyland-Jones B. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 56178
  • 23
    Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 2009; 16: 1617
  • 24
    Saikali Z, Setya H, Singh G, Persad S. Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells. Cancer Cell Int 2008; 8: 10
  • 25
    Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007; 18: 176573
  • 26
    Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006; 12: 1398401
  • 27
    Tatarov O, Mitchell TJ, Seywright M et al. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009; 15: 35409
  • 28
    Yang JC, Ok JH, Busby JE et al. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009; 69: 15160
  • 29
    Pandini G, Mineo R, Frasca F et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005; 65: 184957
  • 30
    Bagnato A, Spinella F, Rosano L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 2008; 86: 47384
  • 31
    Fizazi K, Le Maitre A, Hudes G et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007; 8: 9941000
  • 32
    Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem 2000; 7: 21147
  • 33
    Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 78790
  • 34
    Scher HI, Beer TM, Higano CS et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J Clin Oncol 2009; 27: 15s [abstract 5011]
  • 35
    National Institutes of Health. AFFIRM: A multinational phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Oral MDV3100 in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00974311. Accessed December 2009
  • 36
    Attard G, Reid AH, Olmos D, De Bono JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009; 69: 493740
  • 37
    Attard G, Reid AH, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 37428
  • 38
    National Institutes of Health. A phase 3, randomized, double-blind, placebo-controlled study of abiraterone acetate (CB7630) plus prednisone in patients with metastatic castration-resistant prostate cancer who have failed docetaxel-based chemotherapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00638690. Accessed December 2009
  • 39
    National Institutes of Health. A phase 3, randomized, double-blind, placebo-controlled study of abiraterone acetate (CB7630) plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00887198. Accessed December 2009
  • 40
    Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005; 10 (Suppl. 3): 309
  • 41
    Osoba D, Tannock I. Measuring health-related quality of life. J Clin Oncol 1999; 17: 2293
  • 42
    Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 165463
  • 43
    Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996; 14: 315674
  • 44
    National Institutes of Health. XRP6258 plus prednisone compared to mitoxantrone plus prednisone in hormone refractory metastatic prostate cancer (TROPIC). Available at: http://clinicaltrials.gov/ct2/show/NCT00417079. Accessed December 2009
  • 45
    Galsky MD, Small EJ, Oh WK et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23: 143946
  • 46
    Hussain M, Tangen CM, Lara PN Jr et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23: 87249
  • 47
    Mita AC, Denis LJ, Rowinsky EK et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 72330
  • 48
    Rosenberg JE, Ryan CJ, Weinberg VK et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 2009; 27: 27728
  • 49
    Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 55663
  • 50
    Sternberg CN, Petrylak DP, Witjes F et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC. Results of a randomized phase III trial. J Clin Oncol 2007; 25: 239s [abstract 5019]
  • 51
    Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 2008; 14: 16338
  • 52
    Sternberg CN, Whelan P, Hetherington J et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68: 29
  • 53
    Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 54318
  • 54
    Pivot X, Koralewski P, Hidalgo JL et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19: 154752
  • 55
    Altmann KH. Recent developments in the chemical biology of epothilones. Curr Pharm Des 2005; 11: 1595613
  • 56
    Harzstark AL, Ryan CJ. Therapies in development for castrate-resistant prostate cancer. Expert Rev Anticancer Ther 2008; 8: 25968
  • 57
    Dawson NA. Epothilones in prostate cancer: review of clinical experience. Ann Oncol 2007; 18 Suppl. 5 (v22–7)
  • 58
    Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998; 78: 9404
  • 59
    George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 19326
  • 60
    Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 4019
  • 61
    Ferrer FA, Miller LJ, Lindquist R et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999; 54: 56772
  • 62
    National Institutes of Health. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). Available at: http://clinicaltrials.gov/ct2/show/NCT00519285. Accessed December 2009
  • 63
    National Institutes of Health. Docetaxel and prednisone with or without bevacizumab in treating patients with prostate cancer that did not respond to hormone therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00110214. Accessed December 2009
  • 64
    Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2009; 2: 1618
  • 65
    Armstrong AJ, George DJ. New drug development in metastatic prostate cancer. Urol Oncol 2008; 26: 4307
  • 66
    Chi KN, Ellard SL, Hotte SJ et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008; 19: 74651
  • 67
    Dahut WL, Gulley JL, Arlen PM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 25329
  • 68
    Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 20914
  • 69
    Di Lorenzo G, Figg WD, Fossa SD et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 54: 108994
  • 70
    Dror Michaelson M, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20: 91320
  • 71
    Figg WD, Li H, Sissung T et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007; 99: 104755
  • 72
    Mathew P, Logothetis CJ, Dieringer PY et al. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 2006; 5: 1449
  • 73
    Ning YM, Gulley J, Arlen P et al. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic catration-refractory prostate cancer (CRPC). American Soc Clinical Oncology 2008; Genitourinary Cancers Symposium: Abstract 164.http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confide=54&abstracted=20470. Accessed December 2009
  • 74
    Picus J, Halabi S, Rini B et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003; 22: 393 [abstract 1578]
  • 75
    Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer. history and rationale. Urol Oncol 2006; 24: 2503
  • 76
    Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2009; [Epub ahead of print]. DOI:10.1093/annonc/mdp323
  • 77
    Steinbild S, Mross K, Frost A et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer. a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007; 97: 14805
  • 78
    Figg WD, Retter A, Steinberg SM, Dahut WL. Inhibition of angiogenesis: thalidomide or low molecular-weight heparin? [In Reply. J Clin Oncol 2005; 23: 21134
  • 79
    Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099109
  • 80
    Cumashi A, Tinari N, Rossi C et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008; 270: 22933
  • 81
    Verheul HM, Hammers H, Van Erp K et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007; 13: 42018
  • 82
    Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol 2009; 27: 331924
  • 83
    Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357: 33641
  • 84
    Fizazi K, Yang J, Peleg S et al. Prostate cancer cells–osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003; 9: 258797
  • 85
    Henry D, Von Moos R, Vadhan-Raj S et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer 2009; 7(Suppl.): 11 [abstract 20LBA]
  • 86
    Stopeck A, Body J, Fujiwara Y et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer 2009; 7: (Suppl.):2 [abstract 2LBA]
  • 87
    National Institutes of Health. A randomized, double-blind, multicenter study of denosumab compared with zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00321620. Accessed December 2009
  • 88
    National Institutes of Health. A randomized, double-blind, placebo-controlled, multi-center phase 3 study of denosumab on prolonging bone metastasis-free survival in men with hormone refractory prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00286091. Accessed December 2009
  • 89
    National Institutes of Health. Phase III study of docetaxel and atrasentan versus docetaxel and placebo for patients with advanced hormone refractory prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00134056. Accessed December 2009
  • 90
    Carducci MA, Nelson JB, Saad F et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study. J Clin Oncol 2004; 22: 383 [abstract 4508]
  • 91
    Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 67989
  • 92
    Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009; 182: 50916
  • 93
    Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 156471
  • 94
    James ND, Caty A, Borre M et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 111223
  • 95
    Nelson JB, Love W, Chin JL et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 247887
  • 96
    Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 74555
  • 97
    Smith MR, Saad F, Egerdie B et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009; 182: 26705
  • 98
    Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12: 6296s300s
  • 99
    Fizazi K, Miller K. Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer. BJU Int 2009; 104: 14235
  • 100
    National Institutes of Health. A phase III, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of 10 mg ZD4054 in combination with docetaxel in comparison with docetaxel in patients with metastatic hormone-resistant prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00617669. Accessed December 2009
  • 101
    National Institutes of Health. A phase III trial to test the efficacy of ZD4054, an endothelin A receptor antagonist, versus placebo in patients with hormone resistant prostate cancer (HRPC) and bone metastasis who are pain free and mildly symptomatic. Available at: http://clinicaltrials.gov/ct2/show/NCT00554229. Accessed December 2009
  • 102
    National Institutes of Health. A phase III, randomised, placebo-controlled, double-blind study to assess the efficacy and safety of once-daily orally administered ZD4054 10 mg in non-metastatic hormone-resistant prostate cancer patients. Available at: http://clinicaltrials.gov/ct2/show/NCT00626548. Accessed December 2009
  • 103
    National Institutes of Health. Phase 2 single arm, open-label study of IMC-A12 in asymptomatic, chemotherapy-naïve patients with metastatic androgen-independent prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00520481. Accessed December 2009
  • 104
    National Institutes of Health. A phase 2, randomized, non-comparative, two-arm open label, multiple-center study of CP-751,871 in combination with docetaxel/prednisone in chemotherapy-naive (Arm a) and docetaxel/prednisone refractory (Arm b) patients with hormone insensitive prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00313781. Accessed December 2009
  • 105
    Araujo A, Armstrong AJ, Braud EL et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086). J Clin Oncol 2009; 27: 249s [abstract 5061]
  • 106
    Chi K, Hotte S, Yu et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2009; 27: 238s [abstract 5012]
  • 107
    Lara PN Jr, Longmate J, Evans CP et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009; 20: 17984
  • 108
    Lerut E, Roskams T, Goossens E et al. Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma. J Clin Oncol 2005; 23: 209s [abstract 3071]
  • 109
    Yu EY, Wilding G, Posadas E et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study. J Clin Oncol 2008; 26: 288s [abstract 5156]
  • 110
    Chi KN, Siu LL, Hirte H et al. A phase I study of OGX-011, a 2?-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008; 14: 8339
  • 111
    Miyake H, Hara I, Fujisawa M, Gleave ME. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Invest Drugs 2006; 15: 50717
  • 112
    Sowery RD, Hadaschik BA, So AI et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008; 102: 38997
  • 113
    Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008; 7: 134754
  • 114
    Cao C, Subhawong T, Albert JM et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006; 66: 100407
  • 115
    Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 282531
  • 116
    Morgan TM, Pitts TE, Gross TS et al. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008; 68: 86171
  • 117
    Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008; 3: 3009
  • 118
    Welsbie DS, Xu J, Chen Y et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69: 95866
  • 119
    Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 2009; 4: 5472
  • 120
    Plymate SR, Haugk K, Coleman I et al. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007; 13: 642939
  • 121
    Higano CS, Yu EY, Whiting SH et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 2009; 25: 139s [abstract 3505]
  • 122
    Sachdev D. Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer. Curr Opin Mol Ther 2007; 9: 299304
  • 123
    Sabbatini P, Rowand JL, Groy A et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res 2009; 15: 305867
  • 124
    Furukawa J, Wraight CJ, Freier SM et al. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate 2009; [Epub ahead of print]. DOI:10.1002/pros.21054
  • 125
    Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 2009; 103: 43440
  • 126
    Koreckij T, Nguyen H, Brown LG et al. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009; 101: 2638
  • 127
    National Institutes of Health. A randomized double-blind phase III trial comparing docetaxel combined with dasatinib to docetaxel combined with placebo in castration-resistant prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00744497. Accessed December 2009
  • 128
    National Institutes of Health. BMS CA180-097. A phase II trial of dasatinib (Sprycel®) in subjects with hormone-refractory prostate cancer, previously treated with chemotherapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00570700. Accessed December 2009
  • 129
    Tabernero J, Cervantes A, Hoekman K et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. J Clin Oncol 2007; 25: 143s [abstract 3520]
  • 130
    Drake CG. Immunotherapy for prostate cancer: walk, don’t run. J Clin Oncol 2009; 27: 40357
  • 131
    Fong L, Kwek SS, O’Brien S et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 60915
  • 132
    Gulley JL, Todd N, Dahut WL, Schlom J, Arlen PM. A phase II study of PROSTVAC-VF vaccine, and the role of GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC). J Clin Oncol 2005; 23: 166s [Abstract 2504]
  • 133
    Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 36709
  • 134
    Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 18105
  • 135
    National Institutes of Health. Provenge (sipuleucil-T) active cellular immunotherapy treatment of metastatic prostate cancer after failing hormone therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00065442. Accessed December 2009
  • 136
    Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 308994
  • 137
    Dendreon Corporation Summary of phase 3 IMPACT trial results presented at AUA meeting. Webcast Conference Call April 28, 2009. Available at: http://files.shareholder.com/downloads/DNDN/0x0x290327/0d56dd47-8426-46dd-ab31-705983b009ca/DNDN_42809_IMPACT_Webcast_Slides_FINAL.pdf. Accessed December 2009
  • 138
    Godfrey WR, Blumenstein BA, Schuetz TJ et al. Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). Eur J Cancer 2009; 7: 406 [Abstract O-7002]
  • 139
    National Institutes of Health. Docetaxel in combination with GVAX® Immunotherapy versus docetaxel and prednisone in prostate cancer patients (VITAL-2). Available at: http://clinicaltrials.gov/ct2/show/NCT00133224. Accessed December 2009
  • 140
    National Institutes of Health. GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer (VITAL-1). Available at: http://clinicaltrials.gov/ct2/show/NCT00089856. Accessed December 2009
  • 141
    Ramiah V, George DJ, Armstrong AJ. Clinical endpoints for drug development in prostate cancer. Curr Opin Urol 2008; 18: 3038
  • 142
    Collette L, Burzykowski T, Carroll KJ et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005; 23: 613948
  • 143
    Collette L, Burzykowski T, Schroder FH. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006; 42: 134450
  • 144
    Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: ‘RECIST’ing a step backwards. Clin Cancer Res 2005; 11: 522332
  • 145
    Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007; 13: 148892
  • 146
    Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 396570
  • 147
    Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 114859
  • 148
    Hussain M, Goldman B, Tangen C et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009; 27: 24506
  • 149
    Arlen PM, Bianco F, Dahut WL et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008; 179: 21816